State-of-the-Art PaperBeyond High-Density Lipoprotein Cholesterol Levels: Evaluating High-Density Lipoprotein Function as Influenced by Novel Therapeutic Approaches
Under an Elsevier user license
open archive
Abbreviations and Acronyms
CAD
coronary artery disease
CETP
cholesteryl ester transfer protein
FMD
flow-mediated dilation
HDL
high-density lipoprotein
HUVEC
human umbilical endothelial cell
ICAM
intercellular adhesion molecule
LDL
low-density lipoprotein
NO
nitric oxide
NOS
nitric oxide synthase
RCT
reverse cholesterol transport
TNF
tumor necrosis factor
VCAM
vascular cell adhesion molecule
Cited by (0)
Dr. Rader is supported by grants from the National Heart, Lung, and Blood Institute (HL22633, HL70128) and is a recipient of the Doris Duke Charitable Foundation Distinguished Clinical Scientist Award. Dr. Rader has had research support from and consulted for Abbott Laboratories, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly and Co., Merck, Merck/Schering-Plough, Novartis, Pfizer, and Wyeth on topics related to high-density lipoprotein cholesterol. Dr. deGoma has received honoraria from Abbott Laboratories, AstraZeneca, and Merck/Schering-Plough for speaking on the management of dyslipidemia in clinical practice.
Copyright © 2008 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.